Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH...
Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase...
Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of...
Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN...
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary...
SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary...
Mails Letter to Shareholders Detailing Strength of the Board’s Nominees and Momentum in Advancing Vaxart’s Value Creation Strategy Reinforces that the Dissident’s Nominees Have No Relevant Biotechnology...
Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing...
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders...
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second...